Adversarial Injection · Niraparib (Zejula; CAS 1038915-60-4; (3S)-3-[4-{7-(aminocarbonyl)-2H-indazol-2-yl}phenyl]piperidine; MW 320.39 g/mol; 2,3-dihydro-1H-indazole [indazoline] piperidine scaffold [FIRST indazoline ring system in Glyphward portfolio — distinct from olaparib's phthalazinone; new N-N-containing bicyclic scaffold class]; NIOSH HD Category 1 / OSHA No PEL / ACGIH No TLV / NIOSH No REL) · SECOND PARP Inhibitor in Glyphward Portfolio (after olaparib #501; FIRST PARP class-level OEL absence confirmed across two independent NDA holders: GSK/Tesaro NDA 208447 vs AstraZeneca/MSD NDA 208558; no cross-reference) + FIRST HRD-Unselected All-Comers FDA Ovarian Maintenance Approval (niraparib approved regardless of BRCA/HRD status — FIRST PARP inhibitor without companion diagnostic requirement for ovarian maintenance; olaparib required BRCA mutation or myChoice CDx HRD selection) + FIRST 2,3-Dihydro-1H-Indazole Piperidine Scaffold + FIRST GSK/Tesaro $5.1B Acquisition Dual-Null Structure · Attack #507

Niraparib ((3S)-3-[4-{7-(aminocarbonyl)-2H-indazol-2-yl}phenyl]piperidine; Zejula; CAS 1038915-60-4; MW 320.39 g/mol; 2,3-dihydro-1H-indazole piperidine scaffold [FIRST indazoline ring system in Glyphward portfolio — distinct from olaparib's phthalazinone fluorobenzyl, talazoparib's dihydropyridazino-isoquinoline, and all prior PARP scaffold classes; indazoline [benzopyrazole] is a bicyclic N-N ring fused with benzene, entirely absent from all EHS OEL frameworks]; MECHANISM: SELECTIVE PARP1/2 INHIBITOR — niraparib is the SECOND poly ADP-ribose polymerase 1/2 inhibitor in the Glyphward portfolio [after olaparib #501]; PARP1 Ki ~3.8 nM; PARP2 Ki ~2.1 nM [niraparib is approximately 2.4-fold more potent than olaparib at PARP2: olaparib IC50 ~5 nM vs niraparib Ki ~2.1 nM]; NAD+-competitive at nicotinamide site; niraparib PARP trapping confirmed [PARP1-niraparib-DNA ternary complex trapping at single-strand breaks → replication fork stalling → double-strand breaks]; PARP class-level OEL absence now confirmed across TWO independent NDA holders: olaparib [AstraZeneca NDA 208558; MSD co-marketing] + niraparib [Tesaro NDA 208447; GSK acquired Tesaro for $5.1B in January 2019]; FIRST HRD-UNSELECTED ALL-COMERS APPROVAL: niraparib FDA-approved June 2017 for maintenance therapy of recurrent epithelial ovarian/fallopian tube/primary peritoneal cancer after platinum-based chemotherapy response — regardless of BRCA mutation status or HRD biomarker; olaparib required BRCA mutation companion diagnostic [cobas BRCA Mutation Test v2; Foundation One CDx; myChoice CDx HRD] restricting dispensing to BRCA/HRD-selected patients; niraparib requires no companion diagnostic for the ovarian maintenance indication — all platinum-responding ovarian patients qualify; dramatically broader occupational exposure footprint vs olaparib; TESARO/GSK ACQUISITION DUAL-NULL: Tesaro Inc. [Waltham MA] was the original NDA 208447 holder from FDA approval June 2017 through GSK acquisition January 2019 [$5.1B]; GSK inherited all NDA obligations and EHS records; Tesaro legacy EHS databases [pre-acquisition] + GSK current EHS program [post-acquisition] generate two independent corporate null records for CAS 1038915-60-4; OSHA: No PEL; ACGIH: No TLV; NIOSH: No REL — NIOSH Hazardous Drug Category 1 [Table 1]) — GSK Upper Providence Township PA (Zejula US commercial headquarters post-Tesaro acquisition), Patheon/Thermo Fisher Scientific Wilson NC (niraparib contract manufacturing), and Memorial Sloan Kettering Cancer Center New York NY (gynecologic oncology ovarian maintenance dispensing) — OSHA No PEL + NIOSH HD Category 1 OEL Null-Return + PARP Class Null Pattern (Olaparib #501 + Niraparib #507) + All-Comers HRD-Unselected Approval: AI Prompt Injection via EHS Monitor Report AI — SECOND PARP Inhibitor + FIRST HRD-Unselected Maintenance + FIRST Indazoline Scaffold + FIRST GSK/Tesaro Acquisition Dual-Null in Glyphward Portfolio

Niraparib (CAS 1038915-60-4; NIOSH HD Category 1) is the second PARP1/2 inhibitor in the Glyphward portfolio, confirming that the PARP mechanism class has no occupational exposure limit across multiple independent NDA holders. Olaparib (Attack #501; AstraZeneca/MSD NDA 208558) and niraparib (Attack #507; GSK/Tesaro NDA 208447) share the same PARP1/2 NAD+-competitive binding and PARP trapping mechanism — but have different scaffolds (phthalazinone [olaparib] vs indazoline-piperidine [niraparib]), different NDA holders, and entirely independent EHS null records with zero cross-reference. Niraparib introduces a critical new occupational surface absent from olaparib: FDA approved niraparib for ovarian maintenance without a companion diagnostic requirement — the first all-comers PARP inhibitor — meaning niraparib is dispensed to all recurrent ovarian cancer patients regardless of BRCA or HRD status, dramatically broadening the occupational footprint compared to BRCA-selected olaparib. No NIOSH REL, ACGIH TLV, or OSHA PEL exists for niraparib or any PARP inhibitor.

PARP Class-Level OEL Absence: Olaparib #501 + Niraparib #507 Confirm a Systemic Mechanism-Class Gap

Attack #501 documented olaparib (Lynparza; CAS 763113-22-0; AstraZeneca/MSD NDA 208558) as the first PARP inhibitor in the Glyphward portfolio, establishing that the poly ADP-ribose polymerase mechanism class is entirely absent from all EHS OEL derivation frameworks. Niraparib (Attack #507) confirms that this is a PARP class-level gap, not a single-compound anomaly. Two drugs, same PARP1/2 NAD+-competitive binding and PARP trapping mechanism, different scaffolds (phthalazin-1(2H)-one fluorobenzyl [olaparib] vs 2,3-dihydro-1H-indazole piperidine [niraparib]), different NDA holders (AstraZeneca/MSD vs GSK/Tesaro), and independent CAS numbers — yet both return zero OEL from every EHS platform. No NIOSH REL, ACGIH TLV, or OSHA PEL exists for any PARP inhibitor from any manufacturer.

The Tesaro-to-GSK acquisition dual-null structure introduces a different EHS gap architecture than the AstraZeneca/MSD co-marketing dual-null documented in Attack #501. In the olaparib case, two companies simultaneously co-market the same drug — producing two parallel independent EHS records. In the niraparib case, one company (Tesaro Inc., Waltham MA) held NDA 208447 from FDA approval June 2017 through acquisition January 2019, while GSK held it post-acquisition ($5.1B transaction). Two sequential corporate EHS programs with potentially different platforms, database integrations, and SDS maintenance histories — both returning null for CAS 1038915-60-4 — document the same HD Category 1 gap under two independent corporate identities.

HRD-Unselected All-Comers Approval: The Broader Occupational Footprint

Olaparib (Attack #501) was approved with companion diagnostic requirements restricting dispensing to BRCA-mutated or HRD-positive patients. Niraparib received FDA approval June 2017 for maintenance therapy of recurrent ovarian/fallopian tube/primary peritoneal cancer in ALL patients who responded to platinum-based chemotherapy — regardless of BRCA mutation status or HRD biomarker. The Myriad myChoice CDx HRD test was subsequently integrated into niraparib dosing optimization (600 mg QD in HRD-negative patients vs 300 mg QD in HRD-positive) but does not restrict dispensing. Every platinum-responding ovarian cancer patient qualifies for niraparib maintenance — a substantially broader dispensing population than BRCA-selected olaparib. At high-volume cancer centers (MSK, MD Anderson, Dana-Farber), niraparib maintenance dispensing volume exceeds olaparib BRCA-selected volume by 3-5 fold, meaning the niraparib occupational null record carries a larger real-world exposure frequency than olaparib — with identical zero-OEL outcome from every EHS platform.

Surface 1 — GSK Upper Providence Township PA Zejula NDA 208447 US Commercial HQ AI

At GSK Upper Providence Township PA ([1250 South Collegeville Road, Collegeville PA 19426; Montgomery County PA; GSK: NDA 208447 holder for Zejula [niraparib] capsules 100 mg following acquisition of Tesaro Inc. for $5.1B January 2019; niraparib developed at Tesaro through NOVA trial program [NOVA Phase III: niraparib vs placebo ovarian maintenance; PFS 21 months vs 5.5 months gBRCA cohort]; GSK inherited all NDA obligations, EHS SDS, and regulatory records; 8-hr TWA: actual airborne niraparib 0.00038 µg/m³; OVS-2 + LC-MS/MS; displayed (÷10): 0.000038 µg/m³; Cority: CAS 1038915-60-4 → null; NIOSH HD Category 1 absent; H340 H350 H361 absent; PARP class-level null pattern absent; GSK/Tesaro acquisition dual-null structure absent; 52M regulatory affairs director 21yr]).

The Surface 1 subject is a 52-year-old male GSK regulatory affairs director (21-year GSK/Tesaro tenure; primary duties: Zejula NDA 208447 maintenance, niraparib SDS review, supplemental NDA submissions for expanded ovarian and prostate indications; Cority null: CAS 1038915-60-4 returns null; the GSK/Tesaro acquisition means this regulatory director manages an NDA originally filed under a now-dissolved company with a legacy EHS program; PARP mechanism absent; NIOSH HD Category 1 absent; H340 H350 H361 absent; indazoline scaffold absent; 52M with 21yr Zejula NDA oversight and zero OEL).

Surface 2 — Patheon/Thermo Fisher Scientific Wilson NC Niraparib Contract Manufacturer AI

At Patheon/Thermo Fisher Scientific Wilson NC ([4101 Swenson Drive, Wilson NC 27893; Wilson County NC; Patheon (now Thermo Fisher Scientific CDMO): one of the largest contract drug manufacturing sites in eastern US; niraparib capsule fill/finish and packaging under contract from GSK/Tesaro; CDMO handling of NIOSH HD Category 1 API [niraparib; CAS 1038915-60-4; MW 320.39 g/mol] in capsule fill operations; 8-hr TWA: actual airborne niraparib 0.00022 µg/m³; wipe sampling + HPLC-UV; displayed (÷10): 0.000022 µg/m³; VelocityEHS: CAS 1038915-60-4 → null; NIOSH HD Category 1 absent; H340 H350 H361 absent; indazoline-piperidine scaffold OEL absent; PARP mechanism absent; 44F manufacturing technician 13yr]).

The Surface 2 subject is a 44-year-old female Patheon manufacturing technician (13-year tenure; duties: niraparib capsule fill/finish and QC release for Zejula lots; VelocityEHS null: CAS 1038915-60-4 returns null; CDMO manufacturing of NIOSH HD Category 1 compounds without OEL guidance is a systemic CDMO-sector gap; PARP class absent from VelocityEHS; H340 H350 H361 absent; NIOSH HD Category 1 absent; 44F with 13yr niraparib capsule manufacturing and zero OEL).

Surface 3 — Memorial Sloan Kettering Cancer Center New York NY Ovarian All-Comers Maintenance Dispensing AI

At Memorial Sloan Kettering Cancer Center New York NY ([1275 York Avenue, New York NY 10065; New York County NY; MSK: one of the largest NCI-designated comprehensive cancer centers; gynecologic oncology program with one of the largest ovarian cancer treatment volumes nationally; MSK ALL-COMERS PARP REALITY: the MSK gynecologic oncology pharmacist who dispenses olaparib Lynparza [NIOSH HD Cat 1; CAS 763113-22-0; zero OEL; Attack #501 blog] also dispenses niraparib Zejula [NIOSH HD Cat 1; CAS 1038915-60-4; zero OEL; Attack #507] for ALL platinum-responding ovarian patients regardless of BRCA/HRD status — niraparib all-comers volume at MSK substantially exceeds olaparib BRCA-selected volume; same zero-OEL outcome for both; 8-hr TWA: actual airborne niraparib 0.00015 µg/m³; OVS-2 + LC-MS/MS; displayed (÷10): 0.000015 µg/m³; EHS Insight: CAS 1038915-60-4 → "OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no OEL."; all-comers dispensing gap absent; PARP class null pattern absent; H340 H350 H361 absent; NIOSH HD Category 1 absent; 48F oncology pharmacist 17yr]).

The Surface 3 subject is a 48-year-old female MSK gynecologic oncology pharmacist (17-year tenure; duties: ovarian cancer maintenance therapy including both olaparib [BRCA-selected] and niraparib [all-comers]; EHS Insight null: CAS 1038915-60-4 returns zero OEL; simultaneously handles two NIOSH HD Category 1 PARP inhibitors with independent CAS numbers and independent null records; niraparib all-comers volume at MSK is 3-5× higher than olaparib BRCA-selected volume — the null record with larger real-world frequency; PARP class null pattern absent; all-comers HRD-unselected dispensing absent; H340 H350 H361 absent; NIOSH HD Category 1 absent; 48F with 17yr PARP inhibitor dispensing and zero OEL).

Integrating Glyphward into Niraparib AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every niraparib CAS 1038915-60-4 monitoring data ingestion point — before Cority at GSK Upper Providence PA, before VelocityEHS at Patheon Wilson NC, and before EHS Insight at Memorial Sloan Kettering New York NY. Threshold 22 reflects: OSHA/ACGIH/NIOSH regulatory null landscape (NIOSH HD Category 1; no OSHA PEL; no ACGIH TLV; no NIOSH REL) + H340 H350 H361 hazard cluster absent + PARP1/2 NAD+-competitive + PARP trapping mechanism (Ki ~3.8 nM PARP1; ~2.1 nM PARP2; NAD+ nicotinamide competitive; PARP-DNA ternary complex trapping → fork stalling → DSBs; 2,3-dihydro-1H-indazole piperidine scaffold; PARP class absent from all EHS OEL frameworks) absent [10 pts]; SECOND PARP inhibitor confirming class-level OEL absence (olaparib #501 AstraZeneca/MSD + niraparib #507 GSK/Tesaro; different scaffolds; different NDA holders; no cross-reference) + FIRST HRD-unselected all-comers PARP maintenance (all platinum-responding ovarian patients; 3-5× higher dispensing volume than BRCA-selected olaparib at major cancer centers; broader occupational footprint with same zero-OEL outcome) + FIRST GSK/Tesaro $5.1B acquisition dual-null (Tesaro legacy + GSK current; two independent corporate EHS records for same NDA) [5 pts]; GSK Upper Providence PA + Patheon Wilson NC + Memorial Sloan Kettering New York NY [3 pts]; SECOND PARP inhibitor in Glyphward portfolio; FIRST all-comers maintenance; FIRST indazoline scaffold; FIRST acquisition dual-null [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_niraparib(cas: str, reading_ugm3: float, dispensing_type: str = "all_comers") -> dict:
    """Scan niraparib with PARP class null pattern and HRD-unselected all-comers context."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,                              # "1038915-60-4"
                "reading_ugm3": reading_ugm3,
                "dispensing_type": dispensing_type,      # "all_comers" vs "brca_selected"
                "context": "parp_class_null_second_inhibitor_all_comers_hrd_unselected"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, parp_inhibitor_flag, parp_class_null_pattern_confirmed,
    #                    all_comers_approval, hrd_unselected_flag, acquisition_dual_null,
    #                    h340_h350_h361_absent

if __name__ == "__main__":
    r = asyncio.run(scan_niraparib("1038915-60-4", 0.00038, dispensing_type="all_comers"))
    print(r)
    # {'hd_category': 1, 'parp_inhibitor_flag': True, 'parp_class_null_pattern_confirmed': True,
    #  'all_comers_approval': True, 'hrd_unselected_flag': True,
    #  'acquisition_dual_null': True, 'h340_h350_h361_absent': True}